Novo Nordisk, the leading global health care company, announced the appointment of Hassan Fahmi as the new General Manager for the company’s operations in Egypt effective July 2017. Fahmi has more than 20 years of experience across business development, marketing and communications with proven leadership abilities among leading FMCG corporations and start-ups. Fahmi has held several managerial positions at Novo Nordisk prior to his latest appointment including Business Development Manager, and Marketing and MAPA Director, where he was responsible for the entire diabetes and bio-pharm portfolios, achieving both market share growth and increased sales.

"I am extremely happy Novo Nordisk has given me the privilege of taking on this esteemed position," said Hassan Fahmi, General Manager, Novo Nordisk Egypt. "Egypt is a hub for Novo Nordisk’s operations in the Middle East and Africa and I’m honored to lead the company's operations in Egypt, cooperating with more than 160 employees in the local market and putting Egyptian patients at the top of our priorities. In the coming period, we aim to achieve more growth and expansion in Egypt through initiatives and activities that aim to best serve Egyptian patients, all in cooperation with Ministry of Health and its affiliates.”  

Fahmi has a proven track record of brand-building and leadership, coupled with diverse experience of nearly 24 years in Egypt and the Gulf region that were key to his appointment as General Manager and ability to lead the company’s operations successfully in Egypt.

Fahmi added: “Novo Nordisk creates life changing medications including Tresiba® and Victoza®. Tresiba® is a once-daily basal insulin injection allowing flexibility in day-to-day dosing time, providing ultra-long diabetes treatment beyond 42 hours, therefore, it is recommended for people with diabetes who are fasting during the month of Ramadan, and those who may miss their insulin dose due to the change of daily lifestyle during fasting. It provides glycemic control with a lower risk of nocturnal hypoglycemia, while Victoza® helps patients maintain normal blood sugar levels with a once-daily injection that can be taken at any time of day, irrespective of meals with reduced risk of hypoglycaemia. Furthermore, Victoza® can help patients achieve weight loss, by increasing satiety and delaying gastric empting, and thus reducing caloric intake.  While it also reduces cardiovascular risks. All these medications have several benefits in achieving a better quality of life"  

As a part of its commitment to Egyptian patients, Novo Nordisk has launched numerous initiatives in recent years including the opening of Novo care centers across 16 governorates to raise diabetes awareness among people with the disease and the community. Additionally, Novo Nordisk, in cooperation with Ministry of Health, opened two centers of excellence in Om El Masreyin Hospital in Giza and in Ismailia, providing healthcare services to people with diabetes, in addition to specialized doctors for the treatment of diabetes-related complications free of charge, including ophthalmologists, diabetic feet specialists, cardiologists, and neurologists. The centers will also accommodate medical labs for necessary tests.    

-Ends-

About Novo Nordisk 
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 41,400 people in 77 countries and markets its products in more than 165 countries.

For Further information, please contact:
Media Relations Manager: Abeer El Areeny
Phone:+201025007699 
Email: aaey@novonordisk.com

© Press Release 2017